XXXX associated with interferon beta-1a.

@entity1 @entity17 @entity417 @entity2150 @entity683 @entity15
Subcutaneous interferon beta-1a is a recognized treatment of relapsing @entity15 , and it may delay the onset of definite @entity15 in @entity1 with a first clinical demyelinating episode. Interferon beta-1a exerts beneficial effects on cognitive functioning via both short-term and long-term mechanisms. The beneficial effect is thought to be a result of immune modulation, with inhibition of leukocyte proliferation and antigen presentation and an increased amount of interleukins. The systemic side effects of interferon beta-1a are @entity683 and development of neutralizing antibodies, the clinical significance of which is not known. There have been concerns about the rare development of an acute @entity17 after interferon beta-1a therapy as a result of upregulation of inflammatory mediators. In the clinical trials, there is evidence of development of mild @entity417 with a hemoglobin level below 10 g/dL only in 3% of the @entity1 . There has been no reported case of development of @entity2150 in @entity1 being treated with interferon beta-1a. Described here is a case of development of @entity2150 with interferon beta-1a in a @entity1 with @entity15 . Our @entity1 underwent a complete hematologic evaluation to rule out other causes of @entity2150 . Association with interferon beta-1a was highly suspected.
